AYTU
NASDAQ
US
Aytu BioPharma, Inc. - Common Stock
$2.68
▲ +$0.04
(+1.52%)
Vol 55K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$26.5M
ROE
-48.5%
Margin
-20.5%
D/E
117.29
Beta
0.37
52W
$1–$3
Wall Street Consensus
9 analysts · Apr 20262
Strong Buy
6
Buy
1
Hold
0
Sell
0
Strong Sell
88.9%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 50.0%
Next Report
May 12, 2026
EPS Estimate: $-0.58
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Sep 2026 | $-0.58 | — | — |
| Dec 2025 | $-0.61 | $-1.05 | $-0.44 |
| Sep 2025 | $-0.23 | $0.21 | +$0.44 |
| Jun 2025 | $-0.04 | $-2.92 | $-2.88 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $16.2M | $18.5M | $15.1M | $13.9M | $15.2M |
| Net Income | — | $788K | $4.0M | -$19.8M | $2.0M | -$10.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -47.4% | 5.3% | 5.3% | 5.3% | -48.5% | -48.5% |
| P/E (TTM) | — | 8.11 | 11.25 | 13.73 | — | — |
| Net Margin | -130.9% | 2.4% | 2.4% | 2.4% | -20.5% | -20.5% |
| Gross Margin | 67.8% | 68.6% | 68.6% | 68.6% | 67.6% | 67.6% |
| D/E Ratio | 115.02 | 61.38 | 61.38 | 61.38 | 117.29 | 117.29 |
| Current Ratio | 1.26 | 1.03 | 1.03 | 1.03 | 1.23 | 1.23 |
Key Ratios
ROA (TTM)
-10.7%
P/S (TTM)
0.42
P/B
1.0
EPS (TTM)
$-2.24
CF/Share
$-3.85
Rev Growth 3Y
-11.8%
52W High
$2.82
52W Low
$0.95
$0.95
52-Week Range
$2.82
Financial Health
Free Cash Flow
$3.7M
Net Debt
-$9.1M
Cash
$30.0M
Total Debt
$20.9M
As of Dec 31, 2025
How does AYTU compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
AYTU valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
0.4
▼
92%
below
peers
(5.0)
vs Peers
vs Industry
Undervalued
P/B ratio
1.0
▼
51%
below
peers
(2.1)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
AYTU profitability vs Pharmaceuticals peers
ROE
-48.5%
▲
11%
above
peers
(-54.3%)
vs Peers
vs Industry
In line
Net margin
-20.5%
▲
57%
above
peers
(-47.4%)
vs Peers
vs Industry
Below avg
Gross margin
67.6%
▼
1%
below
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
-10.7%
▲
71%
above
peers
(-37.4%)
vs Peers
vs Industry
Top tier
AYTU financial health vs Pharmaceuticals peers
D/E ratio
117.3
▲
7516%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
1.2
▼
63%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
0.4
▼
61%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
AYTU fundamentals radar
AYTU
Peer median
Industry
AYTU profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
AYTU vs peers: key metrics
Latest News
No related news yet